---
title: "Absolute Benefit of Androgen Deprivation Therapy Added to Radiotherapy for Localized Prostate Canc"
id: "medrxiv-0-absolute-benefit-of-androgen-deprivation-therapy-with-radiotherapy-for"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-absolute-benefit-of-androgen-deprivation-therapy-with-radiotherapy-for"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1?rss=1"
published_at: "2026-09-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Absolute Benefit of Androgen Deprivation Therapy Added to Radiotherapy for Localized Prostate Canc
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-absolute-benefit-of-androgen-deprivation-therapy-with-radiotherapy-for
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1?rss=1)
- **Published At:** 2026-09-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study estimated individualized absolute benefit of adding and prolonging **androgen deprivation therapy (ADT)** to **radiation therapy (RT)** for men with localized prostate cancer by integrating cancer-specific risk and non-cancer mortality. - Cause-specific hazards for prostate cancer outcomes were taken from the validated **STAR-CAP** staging system and non-cancer mortality from the validated **OCCAM** model; ADT efficacy was applied using hazard ratios from the **MARCAP** meta-analysis. - The Prostate, Lung, Colon, and Ovarian (**PLCO**) trial cohort (n=5,468 patients with complete covariates) illustrated model utility. - Primary outcome was the estimated 10-year **absolute risk reduction (ARR)** in **distant metastasis (DM)** from adding short-term ADT (STADT) to RT or extending STADT to long-term ADT (LTADT). - Model-estimated 10-year risk of DM under guideline-concordant care ranged from <1% to 56%; independent **other-cause mortality (OCM)** risk ranged from 3% to 80%. - Among NCCN unfavorable intermediate-risk patients (n=1,814) adding STADT to RT yielded a median 10-year ARR of 4%, with individual ARR ranging from <1% to nearly 15%. - For NCCN high-risk patients (n=1,289), prolonging ADT produced a median ARR of 9% (range 0.4%–17.2%). - There was substantial heterogeneity within conventional risk groups: 25% of unfavorable intermediate-risk patients had ARR <2.4% and 25% of high-risk patients had ARR <5%. - Authors conclude that integrating tumor aggressiveness and comorbidity yields individualized absolute benefit estimates to inform treatment discussions, but external validation is required before clinical use. - Data sources, code, and cause-specific hazards are available on reasonable request; PLCO data access information is provided.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=x6jGu5eFR4DnI8XsrkwJuk3KAG3qJA99UXSTvC8xxTg-1789179979.521169-1.2.1.1-lm1Ypj4Tp8PTrcnVmBRWC7LOZvH322jSIk_7inFMliTx5.GcZRoxicvUZNhickjm) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Absolute Benefit of Androgen Deprivation Therapy With Radiotherapy for Localized Prostate Cancer [ View ORCID Profile](http://orcid.org/0000-0001-8117-5678)Jessica Aldous, William C Jackson, Elizabeth Chase, Elise Covert, Joseph Tang, Udit Singhal, Todd M Morgan, Daniel E Spratt, Robert T Dess, Matthew J Schipper doi: https://doi.org/10.64898/2026.09.10.26362669 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jessica Aldous 1 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2BAldous%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aldous%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJessica%2BAldous%2B) * [ORCID record for Jessica Aldous](http://orcid.org/0000-0001-8117-5678 "Open in new tab") William C Jackson 2 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=William%2BC%2BJackson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jackson%20WC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilliam%2BC%2BJackson%2B) Elizabeth Chase 3 Department of Economics, Sociology, & Statistics, RAND Corporation, Arlington, VA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elizabeth%2BChase%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chase%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElizabeth%2BChase%2B) Elise Covert 4 IQVIA, Madison, WI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elise%2BCovert%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Covert%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElise%2BCovert%2B) Joseph Tang 2 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joseph%2BTang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tang%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoseph%2BTang%2B) Udit Singhal 5 Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Udit%2BSinghal%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Singhal%20U&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AUdit%2BSinghal%2B) Todd M Morgan 5 Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Todd%2BM%2BMorgan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Morgan%20TM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATodd%2BM%2BMorgan%2B) Daniel E Spratt 6 Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine Cleveland, Cleveland, OH, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BE%2BSpratt%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Spratt%20DE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BE%2BSpratt%2B) Robert T Dess 2 Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Robert%2BT%2BDess%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dess%20RT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARobert%2BT%2BDess%2B) Matthew J Schipper 1 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BJ%2BSchipper%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schipper%20MJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMatthew%2BJ%2BSchipper%2B) * For correspondence: mjschipp@med.umich.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1298470/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1298470/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1298470/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1298470/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1298470/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1298470/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objectives: To estimate the absolute benefit of adding and prolonging androgen deprivation therapy (ADT) to radiation therapy (RT) for men with localized prostate cancer by integrating cancer-specific risk, other-cause mortality (OCM) risk, and relative treatment efficacy. Subjects and Methods: Individualized risks were estimated by integrating cause-specific hazard estimates from a validated staging system (STAR-CAP) with those from a validated non-cancer mortality model (OCCAM). ADT treatment efficacy was then incorporated using published hazard ratio estimates from the MARCAP meta-analysis. Model utility was illustrated using the Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial cohort (n=5468 prostate cancer patients with complete covariates). The primary outcome was the estimated 10-year absolute risk reduction (ARR) in distant metastasis (DM) from adding short-term ADT (STADT) to RT or extending STADT to long term ADT (LTADT). Results: Within PLCO, model estimated risk of DM at 10 years ranged from ## Funder Information Declared NIH Common Fund, T32CA83654 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.09.26362633v1 "Virtual environment benefits motor dysfunction in Functional Neurological Disorder: Evidence from Virtual and Augmented Reality")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.10.26362656v1 "Evaluation of AI-assisted summarisation of tertiary clinical genomics reports: results of the QNOMX-VHIR-CPSP-001 Phase 1 study") Posted September 11, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/11/2026.09.10.26362669.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.10.26362669v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/11/2026.09.10.26362669.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Absolute Benefit of Androgen Deprivation Therapy With Radiotherapy for Localized Prostate Cancer Jessica Aldous, William C Jackson, Elizabeth Chase, Elise Covert, Joseph Tang, Udit Singhal, Todd M Morgan, Daniel E Spratt, Robert T Dess, Matthew J Schipper medRxiv 2026.09.10.26362669; doi: https://doi.org/10.64898/2026.09.10.26362669 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362669v1%26text%3DAbsolute%2520Benefit%2520of%2520Androgen%2520Deprivation%2520Therapy%2520With%2520Radiotherapy%2520for%2520Localized%2520Prostate%2520Cancer "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362669v1%26t%3DAbsolute%2520Benefit%2520of%2520Androgen%2520Deprivation%2520Therapy%2520With%2520Radiotherapy%2520for%2520Localized%2520Prostate%2520Cancer "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362669v1%26title%3DAbsolute%2520Benefit%2520of%2520Androgen%2520Deprivation%2520Therapy%2520With%2520Radiotherapy%2520for%2520Localized%2520Prostate%2520Cancer%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362669v1%26title%3DAbsolute%2520Benefit%2520of%2520Androgen%2520Deprivation%2520Therapy%2520With%2520Radiotherapy%2520for%2520Localized%2520Prostate%2520Cancer "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.10.26362669) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.10.26362669v1&count=horizontal&via=&text=Absolute%20Benefit%20of%20Androgen%20Deprivation%20Therapy%20With%20Radiotherapy%20for%20Localized%20Prostate%20Cancer&counturl=www.medrxiv.org/content/10.64898/2026.09.10.26362669v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (616) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (898) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (330) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4800) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (478) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (414) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (647) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1624) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15912) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1200) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7029) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (732) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1063) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5026) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1431) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1756) * [Hematology](https://www.medrxiv.org/collection/hematology) (584) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1341) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16275) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1169) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (667) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (153) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (722) * [Neurology](https://www.medrxiv.org/collection/neurology) (7246) * [Nursing](https://www.medrxiv.org/collection/nursing) (366) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1078) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecol
## Related Clinical Research

- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Hormonal Management in Older Transgender and Gender Diverse Adults: Case-Based Considerations](https://medichelpline.com/clinical-feed/pubmed-42274359.md) (DOI: 10.1210/clinem/dgag231)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [PSMA PET/CT Plus mpMRI Improves Detection of Exclusionary Features for Prostate Cancer Focal Thera](https://medichelpline.com/clinical-feed/medrxiv-19-prostate-specific-membrane-antigen-pet-ct-complements-mri-for-focal-therapy.md)
- [Replacing animal fats with plant fats linked to lower mortality after nonmetastatic prostate cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-swapping-animal-fats-with-plant-fats-may-lower-risk-of-death-after-prostate.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.